WAYNE GOODMAN to Placebos
This is a "connection" page, showing publications WAYNE GOODMAN has written about Placebos.
Connection Strength
0.191
-
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
Score: 0.067
-
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
Score: 0.057
-
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan; 46(1):36-44.
Score: 0.019
-
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
Score: 0.013
-
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997 Sep; 154(9):1293-5.
Score: 0.008
-
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
Score: 0.007
-
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
Score: 0.007
-
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
Score: 0.007
-
Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993 Apr; 150(4):647-9.
Score: 0.006